image
Akebia Therapeutics, Inc. AKBA
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 1.79
-3.76 %
$ 391 M
Market Cap
-8.14
P/E
1. INTRINSIC VALUE

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.[ Read More ]

The intrinsic value of one AKBA stock under the base case scenario is HIDDEN Compared to the current market price of 1.79 USD, Akebia Therapeutics, Inc. is HIDDEN

AKBA Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart AKBA

image
FINANCIALS
195 M REVENUE
-33.49%
Growth Rates
1Year -33.49%
3Years -12.98%
5Years -1.30%
7Years 99.73%
10Years 0.00%
-46.3 M OPERATING INCOME
26.79%
Growth Rates
1Year 26.79%
3Years 50.28%
5Years 23.64%
7Years 14.32%
10Years -11.25%
-51.9 M NET INCOME
43.90%
Growth Rates
1Year 43.90%
3Years 48.65%
5Years 18.41%
7Years 12.83%
10Years -14.71%
-23.4 M OPERATING CASH FLOW
68.03%
Growth Rates
1Year 68.03%
3Years 40.39%
5Years 24.84%
7Years -4.97%
10Years -7.51%
0 INVESTING CASH FLOW
100.00%
Growth Rates
1Year 100.00%
3Years 25.99%
5Years 0.00%
7Years 0.00%
10Years 7.18%
-25.2 M FINANCING CASH FLOW
-172.67%
Growth Rates
1Year -172.67%
3Years -3.50%
5Years -4.75%
7Years -4.67%
10Years -4.78%
35.6 M REVENUE
-18.46%
Growth Rates
1Year -33.49%
3Years -12.98%
5Years -1.30%
7Years 99.73%
10Years 0.00%
-12.5 M OPERATING INCOME
-43.32%
Growth Rates
1Year 26.79%
3Years 50.28%
5Years 23.64%
7Years 14.32%
10Years -11.25%
-20 M NET INCOME
-133.50%
Growth Rates
1Year 43.90%
3Years 48.65%
5Years 18.41%
7Years 12.83%
10Years -14.71%
-6.7 M OPERATING CASH FLOW
33.49%
Growth Rates
1Year 68.03%
3Years 40.39%
5Years 24.84%
7Years -4.97%
10Years -7.51%
-2 K INVESTING CASH FLOW
93.10%
Growth Rates
1Year 100.00%
3Years 25.99%
5Years 0.00%
7Years 0.00%
10Years 7.18%
1.22 M FINANCING CASH FLOW
-83.99%
Growth Rates
1Year -172.67%
3Years -3.50%
5Years -4.75%
7Years -4.67%
10Years -4.78%
Balance Sheet Decomposition Akebia Therapeutics, Inc.
image
Current Assets 118 M
Cash & Short-Term Investments 42.9 M
Receivables 39.3 M
Other Current Assets 35.9 M
Non-Current Assets 124 M
Long-Term Investments 0
PP&E 16 M
Other Non-Current Assets 108 M
Current Liabilities 99.9 M
Accounts Payable 14.6 M
Short-Term Debt 24 M
Other Current Liabilities 61.2 M
Non-Current Liabilities 172 M
Long-Term Debt 80.1 M
Other Non-Current Liabilities 92.3 M
EFFICIENCY
Earnings Waterfall Akebia Therapeutics, Inc.
image
Revenue 195 M
Cost Of Revenue 74.1 M
Gross Profit 120 M
Operating Expenses 201 M
Operating Income -46.3 M
Other Expenses 5.67 M
Net Income -51.9 M
RATIOS
61.90% GROSS MARGIN
61.90%
Averages
1Year 61.90%
3Years 53.70%
5Years 43.50%
7Years 59.07%
10Years -702.95%
-23.77% OPERATING MARGIN
-23.77%
Averages
1Year -23.77%
3Years -56.53%
5Years -76.50%
7Years -73.31%
10Years -940.31%
-26.68% NET MARGIN
-26.68%
Averages
1Year -26.68%
3Years -59.19%
5Years -75.90%
7Years -72.21%
10Years -934.89%
169.78% ROE
169.78%
Averages
1Year 169.78%
3Years -428.42%
5Years -299.48%
7Years -226.98%
10Years -187.01%
-21.48% ROA
-21.48%
Averages
1Year -21.48%
3Years -32.74%
5Years -37.76%
7Years -32.45%
10Years -34.82%
-76.89% ROIC
-76.89%
Averages
1Year -76.89%
3Years -87.78%
5Years -84.52%
7Years -72.86%
10Years -79.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Akebia Therapeutics, Inc.
image
Net Income -51.9 M
Depreciation & Amortization 41.8 M
Capital Expenditures 0
Stock-Based Compensation 9.32 M
Change in Working Capital -20.7 M
Others -15.8 M
Free Cash Flow -23.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Akebia Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for AKBA of $6 , with forecasts ranging from a low of $6 to a high of $6 .
AKBA Lowest Price Target Wall Street Target
6 USD 235.20%
AKBA Average Price Target Wall Street Target
6 USD 235.20%
AKBA Highest Price Target Wall Street Target
6 USD 235.20%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.

image
2.26 USD
CDTX
Overvalued 84.29%

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

image
0.23 USD
XFOR
Overvalued 42.95%

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

image
-0.0187 USD
MCRB
Overvalued 103.40%

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.

image
2.04 USD
CWBR
Undervalued 298.62%

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.

image
-0.0499 USD
OCEA
Overvalued 106.99%

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy.

image
1.06 USD
ENVB
Undervalued 190.33%

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.

image
0.561 USD
ELEV
Undervalued 5.55%

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.

image
3.67 USD
HEPA
Undervalued 439.85%
6. Ownership
Insider Ownership Akebia Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
265 K USD 4
9-12 MONTHS
119 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 months ago
May 13, 2024
Sell 15.1 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 12016
 1.26 USD
6 months ago
May 13, 2024
Sell 43.9 K USD
Dahan Michel
SVP, Chief Operating Officer
- 34840
 1.26 USD
1 year ago
Aug 25, 2023
Sell 31 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 27000
 1.15 USD
8 months ago
Feb 29, 2024
Sell 13.7 K USD
Dahan Michel
SVP, Chief Operating Officer
- 8661
 1.58 USD
8 months ago
Feb 29, 2024
Sell 9.44 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 5974
 1.58 USD
8 months ago
Feb 29, 2024
Sell 73.6 K USD
Butler John P.
CEO and President
- 46570
 1.58 USD
8 months ago
Feb 29, 2024
Sell 11.3 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 7169
 1.58 USD
8 months ago
Feb 27, 2024
Sell 11.3 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 7411
 1.52 USD
8 months ago
Feb 27, 2024
Sell 16.3 K USD
Dahan Michel
SVP, Chief Operating Officer
- 10744
 1.52 USD
8 months ago
Feb 27, 2024
Sell 12.7 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 8367
 1.52 USD
8 months ago
Feb 27, 2024
Sell 57.4 K USD
Butler John P.
CEO and President
- 37733
 1.52 USD
9 months ago
Feb 01, 2024
Sell 78.1 K USD
Butler John P.
CEO and President
- 46489
 1.68 USD
9 months ago
Feb 01, 2024
Sell 40.8 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 24311
 1.68 USD
1 year ago
May 25, 2023
Sell 77.3 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 63186
 1.2229 USD
1 year ago
May 25, 2023
Sell 117 K USD
Dahan Michel
SVP, Chief Operating Officer
- 95478
 1.2229 USD
1 year ago
May 16, 2023
Sell 67.9 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 63567
 1.068 USD
1 year ago
May 16, 2023
Sell 67.9 K USD
Spellman David A
SVP, CFO and Treasurer
- 63567
 1.068 USD
1 year ago
Mar 01, 2023
Sell 33.6 K USD
Butler John P.
CEO and President
- 38259
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 41.5 K USD
Butler John P.
CEO and President
- 47239
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 5.59 K USD
Butler John P.
CEO and President
- 6370
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 4.68 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 5333
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 5.8 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 6613
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 955 USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 1088
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 5.8 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 6613
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 5.62 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 6400
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 974 USD
Burke Steven Keith
SVP, Chief Medical Officer
- 1110
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 7.07 K USD
Dahan Michel
SVP, Chief Operating Officer
- 8058
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 9.19 K USD
Dahan Michel
SVP, Chief Operating Officer
- 10476
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 1.65 K USD
Dahan Michel
SVP, Chief Operating Officer
- 1878
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 5.62 K USD
Spellman David A
SVP, CFO and Treasurer
- 6400
 0.8775 USD
1 year ago
Mar 01, 2023
Sell 711 USD
Spellman David A
SVP, CFO and Treasurer
- 810
 0.8775 USD
1 year ago
Feb 27, 2023
Sell 31.4 K USD
Butler John P.
CEO and President
- 38632
 0.8132 USD
1 year ago
Feb 27, 2023
Sell 6.13 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 7539
 0.8132 USD
1 year ago
Feb 27, 2023
Sell 8.21 K USD
Dahan Michel
SVP, Chief Operating Officer
- 10090
 0.8132 USD
1 year ago
Feb 27, 2023
Sell 6.13 K USD
Spellman David A
SVP, CFO and Treasurer
- 7539
 0.8132 USD
1 year ago
Feb 27, 2023
Sell 5.43 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 6677
 0.8132 USD
2 years ago
Aug 31, 2022
Sell 416 USD
Burke Steven Keith
director: SVP, Chief Medical Officer
- 1147
 0.3625 USD
2 years ago
Jun 03, 2022
Sell 1.65 K USD
GILMAN STEVEN C
director:
- 4567
 0.362 USD
2 years ago
Mar 01, 2022
Sell 53.9 K USD
Butler John P.
CEO and President
- 24811
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 54.3 K USD
Butler John P.
CEO and President
- 25031
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 8.97 K USD
Butler John P.
CEO and President
- 4131
 2.1707 USD
2 years ago
Feb 28, 2022
Sell 54 K USD
Butler John P.
CEO and President
- 25053
 2.1548 USD
2 years ago
Mar 01, 2022
Sell 2.39 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 1100
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 14.2 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 6556
 2.1707 USD
2 years ago
Feb 28, 2022
Sell 15.9 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 7400
 2.1548 USD
2 years ago
Feb 28, 2022
Sell 8.5 K USD
Cotreau Violetta
SVP, Chief Accounting Officer
- 3946
 2.1548 USD
2 years ago
Mar 01, 2022
Sell 14.9 K USD
Dahan Michel
SVP, Chief Operating Officer
- 6873
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 2.67 K USD
Dahan Michel
SVP, Chief Operating Officer
- 1232
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 14.9 K USD
Dahan Michel
SVP, Chief Operating Officer
- 6873
 2.1707 USD
2 years ago
Feb 28, 2022
Sell 14.1 K USD
Dahan Michel
SVP, Chief Operating Officer
- 6555
 2.1548 USD
2 years ago
Mar 01, 2022
Sell 12.5 K USD
Faulkingham Dell
SVP, CCO
- 5748
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 2.08 K USD
Faulkingham Dell
SVP, CCO
- 957
 2.1707 USD
2 years ago
Feb 28, 2022
Sell 14 K USD
Faulkingham Dell
SVP, CCO
- 6479
 2.1548 USD
2 years ago
Mar 01, 2022
Sell 14.9 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 6873
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 2.34 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 1078
 2.1707 USD
2 years ago
Mar 01, 2022
Sell 14.2 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 6556
 2.1707 USD
2 years ago
Feb 28, 2022
Sell 14.1 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 6555
 2.1548 USD
2 years ago
Mar 01, 2022
Sell 1.74 K USD
Spellman David A
SVP, CFO and Treasurer
- 803
 2.1707 USD
2 years ago
Feb 28, 2022
Sell 15.9 K USD
Spellman David A
SVP, CFO and Treasurer
- 7400
 2.1548 USD
2 years ago
Jan 03, 2022
Sell 13.3 K USD
Cotreau Violetta
SVP, Chief Accounting Officer
- 5833
 2.2862 USD
3 years ago
Aug 31, 2021
Sell 2.95 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 1042
 2.83 USD
3 years ago
Jun 07, 2021
Sell 15.2 K USD
GILMAN STEVEN C
Director
- 4567
 3.3202 USD
3 years ago
Apr 01, 2021
Sell 3.24 K USD
Faulkingham Dell
SVP, CCO
- 952
 3.4 USD
3 years ago
Apr 01, 2021
Sell 2.69 K USD
Spellman David A
SVP, CFO and Treasurer
- 790
 3.4 USD
3 years ago
Apr 01, 2021
Sell 3.6 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 1060
 3.4 USD
3 years ago
Apr 01, 2021
Sell 4.12 K USD
Dahan Michel
director: SVP, Chief Operating Officer
- 1211
 3.4 USD
3 years ago
Apr 01, 2021
Sell 4.12 K USD
Dahan Michel
SVP, Chief Operating Officer
- 1211
 3.4 USD
3 years ago
Apr 01, 2021
Sell 14 K USD
Butler John P.
CEO and President
- 4109
 3.4 USD
3 years ago
Apr 01, 2021
Sell 3.68 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 1081
 3.4 USD
3 years ago
Mar 01, 2021
Sell 86 K USD
Butler John P.
CEO and President
- 25316
 3.3961 USD
3 years ago
Mar 01, 2021
Sell 83.8 K USD
Butler John P.
CEO and President
- 24674
 3.3961 USD
3 years ago
Mar 01, 2021
Sell 22.9 K USD
Faulkingham Dell
CCO
- 6749
 3.3961 USD
3 years ago
Mar 01, 2021
Sell 21.4 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 6309
 3.3961 USD
3 years ago
Mar 01, 2021
Sell 27.1 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 7976
 3.3961 USD
3 years ago
Mar 01, 2021
Sell 22.4 K USD
Dahan Michel
SVP, Chief Operating Officer
- 6602
 3.3961 USD
3 years ago
Mar 01, 2021
Sell 27 K USD
Dahan Michel
SVP, Chief Operating Officer
- 7945
 3.3961 USD
3 years ago
Mar 01, 2021
Sell 25.7 K USD
Burke Steven Keith
SVP, Chief Medical Officer
- 7558
 3.3961 USD
4 years ago
Jun 08, 2020
Sell 55.3 K USD
Smith Cynthia
Director
- 4567
 12.1 USD
4 years ago
Jun 05, 2020
Sell 55.2 K USD
GILMAN STEVEN C
Director
- 4567
 12.08 USD
4 years ago
Jun 08, 2020
Sell 55 K USD
GOWEN MAXINE
Director
- 4567
 12.05 USD
4 years ago
Jun 01, 2020
Sell 74.4 K USD
Faulkingham Dell
CCO
- 6426
 11.58 USD
4 years ago
Feb 28, 2020
Sell 60.7 K USD
Dahan Michel
SVP, Chief Operating Officer
- 6972
 8.7 USD
4 years ago
Feb 28, 2020
Sell 61.3 K USD
Hadas Nicole R.
SVP, Chief Legal Officer
- 7050
 8.7 USD
4 years ago
Feb 28, 2020
Sell 60.7 K USD
Amello Jason
SVP, CFO & Treasurer
- 6976
 8.7 USD
4 years ago
Feb 28, 2020
Sell 30 K USD
Tubridy Karen L
SVP, Chief Development Officer
- 3454
 8.7 USD
4 years ago
Nov 20, 2019
Bought 19.9 K USD
GILMAN STEVEN C
Director
+ 5800
 3.43 USD
4 years ago
Nov 20, 2019
Bought 52.8 K USD
Smith Cynthia
Director
+ 15000
 3.52 USD
4 years ago
Nov 20, 2019
Bought 52.8 K USD
Smith Cynthia
Director
+ 15000
 3.52 USD
4 years ago
Nov 20, 2019
Bought 96.7 K USD
Burke Steven Keith
SVP, Chief Medical Officer
+ 27000
 3.58 USD
4 years ago
Nov 20, 2019
Bought 172 K USD
Butler John P.
CEO and President
+ 50000
 3.44 USD
4 years ago
Nov 20, 2019
Bought 170 K USD
ADAMS ADRIAN
Director
+ 50000
 3.41 USD
6 years ago
Feb 15, 2018
Sell 14.6 K USD
Nash Duane
Director
- 1000
 14.62 USD
7 years ago
Oct 02, 2017
Sell 23.3 K USD
Nash Duane
Director
- 1188
 19.64 USD
7 years ago
Oct 02, 2017
Sell 23.3 K USD
Nash Duane
Director
- 1188
 19.64 USD
7 years ago
Oct 02, 2017
Sell 30.5 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1553
 19.64 USD
7 years ago
Oct 02, 2017
Sell 125 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 6250
 19.95 USD
7 years ago
Oct 02, 2017
Sell 27.5 K USD
Dahan Michel
SVP, Chief Business Officer
- 1398
 19.64 USD
7 years ago
Sep 28, 2017
Sell 96.5 K USD
Dahan Michel
SVP, Chief Business Officer
- 5000
 19.3 USD
7 years ago
Aug 15, 2017
Sell 75 K USD
Dahan Michel
SVP, Chief Business Officer
- 5000
 15 USD
7 years ago
Jul 05, 2017
Bought 15 M USD
Satter Muneer A
Director
+ 1034482
 14.5 USD
7 years ago
Jul 03, 2017
Sell 19.9 K USD
Dahan Michel
SVP, Chief Business Officer
- 1399
 14.2577 USD
7 years ago
Jul 03, 2017
Sell 22.2 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1554
 14.2577 USD
7 years ago
Jul 03, 2017
Sell 14.1 K USD
Nash Duane
Director
- 990
 14.27 USD
7 years ago
Apr 03, 2017
Sell 12.9 K USD
Dahan Michel
SVP, Chief Business Officer
- 1401
 9.1775 USD
7 years ago
Apr 03, 2017
Sell 9.12 K USD
Nash Duane
Director
- 991
 9.2021 USD
7 years ago
Apr 03, 2017
Sell 14.3 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1556
 9.1775 USD
7 years ago
Jan 01, 2017
Sell 17.1 K USD
Dahan Michel
SVP, Chief Business Officer
- 1629
 10.4906 USD
7 years ago
Jan 03, 2017
Sell 20.7 K USD
Nash Duane
Director
- 1980
 10.4601 USD
7 years ago
Jan 01, 2017
Sell 19 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1810
 10.4906 USD
8 years ago
Oct 03, 2016
Sell 17.7 K USD
Nash Duane
Director
- 1981
 8.9581 USD
8 years ago
Oct 01, 2016
Sell 12.5 K USD
Dahan Michel
SVP, Chief Business Officer
- 1401
 8.9548 USD
8 years ago
Oct 01, 2016
Sell 13.9 K USD
Hadas Nicole R.
director: SVP, General Counsel, Sec.
- 1556
 8.9548 USD
8 years ago
Jul 06, 2016
Sell 14.8 K USD
Nash Duane
Director
- 1980
 7.4841 USD
8 years ago
Jul 05, 2016
Sell 10.5 K USD
Dahan Michel
SVP, Chief Business Officer
- 1402
 7.4665 USD
8 years ago
Jul 05, 2016
Sell 11.6 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1557
 7.4665 USD
8 years ago
Apr 04, 2016
Sell 14.6 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1556
 9.41 USD
8 years ago
Apr 04, 2016
Sell 13.2 K USD
Dahan Michel
SVP, Chief Business Officer
- 1401
 9.41 USD
8 years ago
Jan 04, 2016
Sell 22.2 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1811
 12.28 USD
9 years ago
Oct 02, 2015
Sell 8.62 K USD
Nash Duane
Director
- 996
 8.6519 USD
9 years ago
Oct 02, 2015
Sell 12.9 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1484
 8.6657 USD
9 years ago
Jul 02, 2015
Sell 9.49 K USD
Nash Duane
Director
- 996
 9.528 USD
9 years ago
Jul 02, 2015
Sell 9.49 K USD
Nash Duane
Director
- 996
 9.528 USD
9 years ago
Jul 02, 2015
Sell 14.2 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1484
 9.5421 USD
9 years ago
Apr 02, 2015
Sell 13.5 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1483
 9.0881 USD
9 years ago
Jan 02, 2015
Sell 19.7 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1715
 11.4607 USD
9 years ago
Apr 02, 2015
Sell 9.05 K USD
Nash Duane
Director
- 996
 9.0881 USD
9 years ago
Jan 02, 2015
Sell 11.4 K USD
Nash Duane
Director
- 995
 11.4607 USD
9 years ago
Dec 24, 2014
Sell 76.2 K USD
Nash Duane
Director
- 6764
 11.2639 USD
9 years ago
Dec 26, 2014
Sell 57.8 K USD
Nash Duane
Director
- 5169
 11.1909 USD
9 years ago
Apr 22, 2015
Bought 3.46 M USD
Satter Muneer A
Director
+ 420000
 8.25 USD
9 years ago
Apr 02, 2015
Sell 9.05 K USD
Nash Duane
Director
- 996
 9.0881 USD
9 years ago
Apr 02, 2015
Sell 13.5 K USD
Hadas Nicole R.
SVP, General Counsel, Sec.
- 1483
 9.0881 USD
9 years ago
Jan 02, 2015
Sell 19.7 K USD
Hadas Nicole R.
VP General Counsel & Secretary
- 1715
 11.4607 USD
9 years ago
Jan 01, 2015
Sell 11.4 K USD
Nash Duane
Director
- 995
 11.4607 USD
9 years ago
Dec 24, 2014
Sell 76.2 K USD
Nash Duane
Director
- 6764
 11.2639 USD
9 years ago
Dec 26, 2014
Sell 57.8 K USD
Nash Duane
Director
- 5169
 11.1909 USD
9 years ago
Dec 29, 2014
Bought 11.6 K USD
Butler John P.
CEO and President
+ 1000
 11.5672 USD
9 years ago
Dec 24, 2014
Sell 76.2 K USD
Nash Duane
Director
- 6764
 11.2639 USD
9 years ago
Dec 26, 2014
Sell 57.8 K USD
Nash Duane
Director
- 5169
 11.1909 USD
9 years ago
Dec 22, 2014
Bought 11.9 K USD
Butler John P.
CEO and President
+ 1000
 11.916 USD
9 years ago
Dec 15, 2014
Bought 11.3 K USD
Butler John P.
CEO and President
+ 1000
 11.3364 USD
9 years ago
Dec 02, 2014
Bought 59.6 K USD
Renaud Ronald C JR
Director
+ 5000
 11.9173 USD
9 years ago
Nov 26, 2014
Bought 13.2 K USD
Amello Jason
SVP, CFO & Treasurer
+ 1000
 13.22 USD
9 years ago
Nov 25, 2014
Bought 65.9 K USD
Satter Muneer A
Director
+ 5000
 13.18 USD
9 years ago
Nov 24, 2014
Bought 69.4 K USD
Satter Muneer A
Director
+ 5000
 13.88 USD
9 years ago
Nov 21, 2014
Bought 73.6 K USD
Satter Muneer A
Director
+ 5000
 14.73 USD
10 years ago
Nov 20, 2014
Bought 73.5 K USD
Satter Muneer A
Director
+ 5000
 14.7 USD
10 years ago
Nov 19, 2014
Bought 74.2 K USD
Satter Muneer A
Director
+ 5000
 14.85 USD
10 years ago
Nov 18, 2014
Bought 69.2 K USD
Satter Muneer A
Director
+ 5000
 13.84 USD
10 years ago
Nov 17, 2014
Bought 64.7 K USD
Satter Muneer A
Director
+ 5000
 12.94 USD
10 years ago
Nov 14, 2014
Bought 59.6 K USD
Satter Muneer A
Director
+ 5000
 11.91 USD
10 years ago
Nov 13, 2014
Bought 57.8 K USD
Satter Muneer A
Director
+ 5000
 11.56 USD
10 years ago
Nov 13, 2014
Bought 15.4 K USD
GOWEN MAXINE
Director
+ 1300
 11.819 USD
10 years ago
Nov 12, 2014
Bought 10.3 K USD
Butler John P.
CEO and President
+ 1000
 10.305 USD
10 years ago
Nov 12, 2014
Bought 47.6 K USD
Satter Muneer A
Director
+ 3900
 12.2 USD
10 years ago
Nov 12, 2014
Bought 11.9 K USD
Satter Muneer A
Director
+ 1100
 10.85 USD
10 years ago
Mar 25, 2014
Bought 3.1 M USD
Novartis Bioventures Ltd
10 percent owner
+ 182590
 17 USD
10 years ago
Mar 25, 2014
Bought 25.5 K USD
WYZGA MICHAEL S
Director
+ 1500
 17 USD
10 years ago
Mar 25, 2014
Bought 59.5 K USD
Hadas Nicole R.
See Remarks
+ 3500
 17 USD
10 years ago
Mar 25, 2014
Bought 1.55 M USD
Satter Muneer A
Director
+ 91295
 17 USD
10 years ago
Mar 25, 2014
Bought 235 K USD
Butler John P.
President and CEO
+ 13850
 17 USD
10 years ago
Mar 25, 2014
Bought 68 K USD
Amello Jason
SVP, CFO & Treasurer
+ 4000
 17 USD
10 years ago
Mar 25, 2014
Bought 3.1 M USD
Novo A/S
10 percent owner
+ 182590
 17 USD
7. News
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat)  CAMBRIDGE, Mass. , Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia. prnewswire.com - 3 days ago
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT. prnewswire.com - 5 days ago
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Good day and thank you for standing by. seekingalpha.com - 1 week ago
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. zacks.com - 1 week ago
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code Akebia to Host Conference Call at 8:00 a.m. ET on November 7 CAMBRIDGE, Mass. prnewswire.com - 1 week ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. , Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 20,000 shares of Akebia's common stock on October 31, 2024. prnewswire.com - 2 weeks ago
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass. prnewswire.com - 2 weeks ago
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers  CAMBRIDGE, Mass. , Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo® (vadadustat) for patients on dialysis. prnewswire.com - 3 weeks ago
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 Vadadustat clinical data on display for nephrologist and healthcare providers in advance of U.S. market availability expected in January 2025 CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2024 (ASN Kidney Week), which will take place in San Diego, CA from October 24-27. prnewswire.com - 1 month ago
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate A HCPCS code has also been assigned to Vafseo to facilitate reimbursement at dialysis organizations CAMBRIDGE, Mass. , Oct. 10, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that Vafseo® (vadadustat) meets the criteria for the Transitional Drug Add-On Payment Adjustment (TDAPA) in the anemia management end-stage renal disease (ESRD) prospective payment system functional category, beginning on January 1, 2025. prnewswire.com - 1 month ago
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis U.S. Renal Care is a leading provider of in-center and home dialysis in the United States CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's fastest-growing dialysis provider, today announced entry into a multi-year commercial supply contract encompassing all USRC dialysis centers. prnewswire.com - 1 month ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 111,600 shares of Akebia's common stock on September 30, 2024. prnewswire.com - 1 month ago
8. Profile Summary

Akebia Therapeutics, Inc. AKBA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 391 M
Dividend Yield 0.00%
Description Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Contact 245 First Street, Cambridge, MA, 02142 https://www.akebia.com
IPO Date March 20, 2014
Employees 167
Officers Mr. Erik John Ostrowski M.B.A. Senior Vice President, Chief Financial Officer & Chief Business Officer Mr. Richard C. Malabre Chief Accounting Officer Mr. John P. Butler MBA Chief Executive Officer, President & Director Ms. Kimberly Garko Senior Vice President & Chief Technical Officer Ms. Carolyn Rucci Senior Vice President of Legal, General Counsel & Secretary Ms. Meredith Bowman Senior Vice President & Chief People Officer Ms. Tracey Vetterick Vice President of Portfolio Strategy & Corporate Administration Dr. Steven Keith Burke M.D. Senior Vice President of Research & Development and Chief Medical Officer Mercedes Carrasco Senior Director of Investor & Corporate Communications Mr. Nicholas Grund Senior Vice President & Chief Commercial Officer